BRIEF published on 01/31/2025 at 12:15, 2 months 13 days ago Marinomed Biotech AG Announces Management Board Changes CFO Resignation Marinomed Biotech AG Financial Restructuring Management Changes Marinosolv Platform
PRESS RELEASE published on 01/31/2025 at 12:10, 2 months 13 days ago Marinomed Biotech AG: Changes to the Management Board Marinomed Biotech AG announces CFO resignation and appointment of interim finance manager. Successful completion of restructuring and securing financing by selling Carragelose business unit Restructuring CFO Resignation Marinomed Biotech AG Carragelose Interim Finance Manager
BRIEF published on 01/20/2025 at 07:50, 2 months 24 days ago Marinomed Biotech AG Completes Restructuring Proceedings Restructuring Insolvency Business Sale Marinomed Biotech Creditor Approval
BRIEF published on 01/20/2025 at 07:50, 2 months 24 days ago Marinomed Biotech AG achève sa restructuration Restructuration Insolvabilité Vente D'entreprise Biotechnologie Marinomed Approbation Du Créancier
PRESS RELEASE published on 01/20/2025 at 07:45, 2 months 24 days ago Marinomed Biotech AG: Restructuring proceedings successfully completed Marinomed Biotech AG successfully completes restructuring proceedings, fulfilling plan to be funded by Carragelose business sale and Marinosolv asset commercialization Commercialization Marinomed Biotech AG Carragelose Restructuring Proceedings Marinosolv Asset
BRIEF published on 12/19/2024 at 12:44, 3 months 25 days ago Marinomed Biotech AG Approves Sale of Carragelose Division Board Changes Strategic Focus Marinomed Biotech AG Sale Approval Carragelose Division
BRIEF published on 12/19/2024 at 12:44, 3 months 25 days ago Marinomed Biotech AG approuve la vente de sa division Carragelose Marinomed Biotech AG Orientation Stratégique Changements Au Sein Du Conseil D'administration Approbation De La Vente Division De Carragelose
PRESS RELEASE published on 12/19/2024 at 12:39, 3 months 25 days ago Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division Marinomed Biotech AG's extraordinary general meeting approves sale of Carragelose division, ensuring implementation of restructuring plan. Dr. Karl Mahler elected to the Supervisory Board Supervisory Board Marinomed Biotech AG Restructuring Plan Sale Approval Carragelose Division
BRIEF published on 12/17/2024 at 13:05, 3 months 27 days ago Marinomed Biotech AG franchit une étape importante dans sa restructuration Obligation Convertible Financement Des Biotechnologies Vente De Carraghénose Restructuration De Marinomed Accord BEI
BRIEF published on 12/17/2024 at 13:05, 3 months 27 days ago Marinomed Biotech AG Achieves Restructuring Milestone Convertible Bond Carragelose Sale Marinomed Restructuring EIB Agreement Biotech Finance
Published on 04/12/2025 at 15:45, 1 day 14 hours ago New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presid
Published on 04/12/2025 at 02:00, 2 days 4 hours ago Battery X Metals Announces Provisional Patent Application with United States Patent & Trademark Office for Lithium-Ion Battery Rebalancing Technology Innovations
Published on 04/12/2025 at 00:10, 2 days 6 hours ago Applied Minerals, Inc. Files Motion to Approve Disclosure Statement
Published on 04/11/2025 at 23:45, 2 days 6 hours ago Gold Terra Closes First Tranche of Financing Package with Support from Osisko Gold Royalties
Published on 04/11/2025 at 21:45, 2 days 8 hours ago OPPO Unveils Agentic AI Initiative at Google Cloud Next 2025, Showcasing Innovations and Leadership in AI Experiences
Published on 04/11/2025 at 18:38, 2 days 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/11/2025 at 18:23, 2 days 12 hours ago EQS-Adhoc: Cherry SE: Cherry SE recognizes asset impairment for 2024; updates adjusted EBITDA margin for fiscal year 2024
Published on 04/11/2025 at 18:30, 2 days 12 hours ago Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:30, 2 days 12 hours ago Reclassement d'actions au sein du concert familial Feuillet sans incidence sur le contrôle de la société
Published on 04/11/2025 at 18:00, 2 days 12 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/03/2025
Published on 04/11/2025 at 18:00, 2 days 12 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Published on 04/11/2025 at 17:50, 2 days 12 hours ago Mise à disposition du Rapport Financier Annuel 2024
